课题基金 / 基金详情

Real-time PCR expression profiling of microRNA

Real-time PCR expression profiling of microRNA
microRNA 的实时 PCR 表达谱
批准号:
7137111
负责人:
THOMAS D. SCHMITTGEN
金额:
$21.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-25 至 2008-05-31

项目摘要

项目成果

THOMAS D. SCHMITTGEN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):microRNA是一类新发现的内源性小干扰RNA。MicroRNA与信使RNA结合并抑制蛋白质水平。虽然仅在人类中就发现了300多种microRNA,但它们的生物学功能、靶点、表达水平和在疾病中的作用仍在很大程度上未知。已经提出了microRNA表达和癌发生之间的作用。目前缺乏灵敏的高通量方法来监测microRNA的表达。microRNA是具有挑战性的分子,因为microRNA前体由稳定的发夹组成,成熟的microRNA长度仅为22个核苷酸。我们建议评估敏感和特异性的实时PCR检测,以量化成熟和microRNA前体的表达。microRNA表达将在与人类癌症相关的许多重要生物学条件下进行分析。将在通过激光捕获显微切割分离的癌症和正常组织的特定切片中确定microRNA表达。将使用实时PCR和cDNA微阵列比较成熟和前体microRNA的表达。将在人类胰腺癌的临床样本中研究microRNA的表达。实时PCR应用于这类新的令人兴奋的调节RNA的无与伦比的灵敏度和特异性应该推动该领域进入新的方向,不仅在癌症,而且在人类健康的其他领域。
英文摘要
DESCRIPTION (provided by applicant): microRNA is a newly discovered class of endogenous, small interfering RNA. MicroRNA binds to messenger RNA and translationally represses protein levels. While over 300 microRNAs have been discovered in humans alone, their biological function, targets, expression levels and role in disease remain largely unknown. A role between microRNA expression and carcinogenesis has been proposed. There is a lack of sensitive, high-throughput methodologies to monitor the expression of microRNAs. microRNA are challenging molecules to quantify because the microRNA precursors consists as a stable hairpin and the mature microRNA is only 22 nucleotides in length. We propose to evaluate sensitive and specific real-time PCR assays to quantify the expression of the mature and microRNA precursors. The microRNA expression will be analyzed in a number of important biological conditions relating to human cancer. The microRNA expression will be determined in specific sections of cancer and normal tissue isolated by laser-capture microdissection. The expression of mature and precursor microRNAs will be compared to using real-time PCR and a cDNA micro array. microRNA expression will be studied in clinical samples of human pancreatic cancer. The unparallel sensitivity and specificity of real-time PCR as applied to this new and exciting class of regulatory RNAs should propel the field into new directions not only in cancer but in other areas of human health.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1111/j.1582-4934.2008.00483.x
发表时间: 2008-10
期刊: Journal of cellular and molecular medicine
影响因子: 5.3
作者: [Schmittgen TD]
通讯作者: Schmittgen TD
DOI: 10.1158/0008-5472.can-11-1144
发表时间: 2011-12-15
期刊: Cancer research
影响因子: 11.2
作者: [Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, Phelps MA, Papenfuss TL, Croce CM, Patel T, Schmittgen TD]
通讯作者: Schmittgen TD
DOI: 10.2144/000113068
发表时间: 2009-02
期刊: BioTechniques
影响因子: 2.7
作者: [Nuovo G, Lee EJ, Lawler S, Godlewski J, Schmittgen T]
通讯作者: Schmittgen T
DOI: 10.1016/j.bbrc.2011.02.065
发表时间: 2011-03-25
期刊: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子: 3.1
作者: [Park, Jong-Kook, Henry, Jon C., Jiang, Jinmai, Esau, Christine, Gusev, Yuriy, Lerner, Megan R., Postier, Russell G., Brackett, Daniel J., Schmittgen, Thomas D.]
通讯作者: Schmittgen, Thomas D.
共 7 条
    R21 MPI microRNA directed therapy for treating early stage pancreatic cancer
    • 批准号:
      10577609
    • 项目类别:
    • 资助金额:
      $17.82万
    • 财政年份:
      2023
    • 负责人:
      THOMAS D. SCHMITTGEN
    • 依托单位:
    Pilot Project 3: Contribution of Racial Disparity towards the Early Development of Pancreatic Cancer
    • 批准号:
      10006214
    • 项目类别:
    • 资助金额:
      $11.3万
    • 财政年份:
      2018
    • 负责人:
      THOMAS D. SCHMITTGEN
    • 依托单位:
    Project 3 ADM
    • 批准号:
      10762126
    • 项目类别:
    • 资助金额:
      $11.6万
    • 财政年份:
      2018
    • 负责人:
      THOMAS D. SCHMITTGEN
    • 依托单位:
    miRNA Biomarkers for Hepatocellular Carcinoma Associated with Viral Hepatitis
    • 批准号:
      8520269
    • 项目类别:
    • 资助金额:
      $16.77万
    • 财政年份:
      2012
    • 负责人:
      THOMAS D. SCHMITTGEN
    • 依托单位:
    国内基金
    海外基金
    靶向Human ZAG蛋白的降糖小分子化合物筛选以及疗效观察
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      胡文静
    • 依托单位:
    新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
    • 批准号:
      82370885
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      姚晨
    • 依托单位:
    自闭症相关基因CHD8在非人灵长类大脑发育中的作用
    HBV S-Human ESPL1融合基因在慢性乙型肝炎发病进程中的分子机制研究
    • 批准号:
      81960115
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      34.0万元
    • 批准年份:
      2019
    • 负责人:
      江建宁
    • 依托单位: